Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus

Nathan P. Wiederhold; Laura K. Najvar; Rosie Jaramillo; Marcos Olivo; Brian L. Wickes; Gabriel Catano; Thomas F. Patterson

doi:10.1128/AAC.01165-19

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus

Nathan P. Wiederhold, Laura K. Najvar, Rosie Jaramillo, Marcos Olivo, Brian L. Wickes, Gabriel Catano, Thomas F. Patterson

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus. Survival was significantly improved in mice treated with each dose of rezafungin and supratherapeutic posaconazole (20 mg/kg twice daily). Kidney fungal burden, as measured by quantitative real-time PCR, was also significantly reduced in mice treated with rezafungin although variability was observed.

Original language	English (US)
Article number	e01165-19
Journal	Antimicrobial agents and chemotherapy
Volume	63
Issue number	10
DOIs	https://doi.org/10.1128/AAC.01165-19
State	Published - 2019

Keywords

Aspergillus fumigatus
Azole resistance
Invasive aspergillosis
Murine model
Rezafungin
TR34/L98H

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.01165-19

Cite this

@article{d882c34da49545f0888cd637fa2db479,

title = "Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus",

abstract = "We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus. Survival was significantly improved in mice treated with each dose of rezafungin and supratherapeutic posaconazole (20 mg/kg twice daily). Kidney fungal burden, as measured by quantitative real-time PCR, was also significantly reduced in mice treated with rezafungin although variability was observed.",

keywords = "Aspergillus fumigatus, Azole resistance, Invasive aspergillosis, Murine model, Rezafungin, TR34/L98H",

author = "Wiederhold, {Nathan P.} and Najvar, {Laura K.} and Rosie Jaramillo and Marcos Olivo and Wickes, {Brian L.} and Gabriel Catano and Patterson, {Thomas F.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2019 Wiederhold et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.",

year = "2019",

doi = "10.1128/AAC.01165-19",

language = "English (US)",

volume = "63",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "10",

}

TY - JOUR

T1 - Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus

AU - Wiederhold, Nathan P.

AU - Najvar, Laura K.

AU - Jaramillo, Rosie

AU - Olivo, Marcos

AU - Wickes, Brian L.

AU - Catano, Gabriel

AU - Patterson, Thomas F.

PY - 2019

Y1 - 2019

N2 - We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus. Survival was significantly improved in mice treated with each dose of rezafungin and supratherapeutic posaconazole (20 mg/kg twice daily). Kidney fungal burden, as measured by quantitative real-time PCR, was also significantly reduced in mice treated with rezafungin although variability was observed.

AB - We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus. Survival was significantly improved in mice treated with each dose of rezafungin and supratherapeutic posaconazole (20 mg/kg twice daily). Kidney fungal burden, as measured by quantitative real-time PCR, was also significantly reduced in mice treated with rezafungin although variability was observed.

KW - Aspergillus fumigatus

KW - Azole resistance

KW - Invasive aspergillosis

KW - Murine model

KW - Rezafungin

KW - TR34/L98H

UR - http://www.scopus.com/inward/record.url?scp=85072559503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072559503&partnerID=8YFLogxK

U2 - 10.1128/AAC.01165-19

DO - 10.1128/AAC.01165-19

M3 - Article

C2 - 31405851

AN - SCOPUS:85072559503

SN - 0066-4804

VL - 63

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 10

M1 - e01165-19

ER -

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this